https://doi.org/10.1615/critreveukaryotgeneexpr.2013006875
F
Farjana Fattah
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
109
Papers
2.4K
Citations
24
h-index
33
i10-index
Farjana Fattah is an academic researcher from Loma Linda University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lung Cancer Treatments and Mutations & RNA modifications and cancer. The author has an h-index of 24, co-authored 93 publications.
ORCID: 0000-0002-7897-2788Papers by this author
worksReview of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases
2013 · Critical Reviews in Eukaryotic Gene Expression · 596 citations
Immune dysregulation in cancer patients developing immune-related adverse events
2018 · British Journal of Cancer · 180 citations
https://doi.org/10.1038/s41416-018-0155-1
NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone
2015 · Cell Death and Disease · 91 citations
https://doi.org/10.1038/cddis.2014.564
Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
2022 · Cancer Immunology Immunotherapy · 30 citations
https://doi.org/10.1007/s00262-022-03151-2
XRN2 interactome reveals its synthetic lethal relationship with PARP1 inhibition
2020 · Scientific Reports · 14 citations
https://doi.org/10.1038/s41598-020-71203-7
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced <i>KRAS</i> -Mutant Non–Small Cell Lung Cancer
2024 · Clinical Cancer Research · 6 citations
https://doi.org/10.1158/1078-0432.ccr-24-1722
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat